Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Rob White

Patient involvement in health technology assessment

Patients can improve the quality, relevance and value of HTA for all pharma stakeholders

The kind of data that affiliates want

The right kind of data builds affiliate support for international digital marketing.

Anthill Agency

The big dilemma in international digital pharma marketing

How to get consistent international marketing while meeting local affiliates’ needs.

Anthill Agency

- PMLiVE

Mylan gets first biosimilar Herceptin OK from FDA

Ogivri approved by US regulators for all of Roche blockbuster's indications

- PMLiVE

First Herceptin biosimilar cleared in Europe

Ontruzant is approved for all the same indications as Roche’s blockbuster

- PMLiVE

Exploring serious market access roadblocks for rare bleeding disorders

Ensuring that sufferers get the treatment they require

- PMLiVE

AbbVie deal with Amgen sets biosimilar Humira launch dates

Agreement will see Europe access the drug over four years earlier than patients in the US

- PMLiVE

Amgen’s Mvasi is first FDA-approved cancer biosimilar

Offers prospect of lower-cost alternative to Roche's Avastin

Biosimilars: what the future looks like

Biosimilars: what the future looks like

- PMLiVE

Roche faces prospect of second Rituxan biosimilar in US

FDA begins its review of Sandoz's version of the immunotherapy treatment

- PMLiVE

The sound of silence puts the squeeze on generics and biosimilars

Medicines for Europe vows to get  governments talking to realise potential

- PMLiVE

Biocon backs away from biosimilar filings in Europe

EMA asks biotech to withdraw Herceptin and Neulasta biosimilar filings

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links